Patents Assigned to ONO Pharmaceutical Co., Ltd.
  • Compound having selective EP2 agonist activity
    Patent number: 9890146
    Abstract: A compound represented by general formula (I) wherein all symbols are as defined in the specification, a salt or N-oxide of the compound, or a solvate or prodrug of the compound or the salt or N-oxide has a selective EP2 agonist activity and is highly safe, and is therefore useful as a drug, especially as a therapeutic agent for EP2 receptor-related diseases including immune diseases, allergic diseases, neuronal death, dysmenorrhea, premature birth, miscarriage, baldness, ocular diseases, erectile dysfunction, arthritis, lung injury, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, bone diseases, cartilage injury and others.
    Type: Grant
    Filed: February 26, 2015
    Date of Patent: February 13, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Seiji Ogawa, Toshihide Watanabe, Isamu Sugimoto, Kousuke Tani, Kazumi Moriyuki, Yoshikazu Goto, Shinsaku Yamane
  • Purinone derivative
    Patent number: 9879013
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: January 30, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo Yamamoto, Toshio Yoshizawa
  • Methods of producing anamorelin hydrochloride having controlled chloride content
    Patent number: 9872883
    Abstract: The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.
    Type: Grant
    Filed: April 21, 2016
    Date of Patent: January 23, 2018
    Assignees: HELSINN HEALTHCARE SA, ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shin-itsu Kuwabe, Takehiko Yanagimachi, Hideyuki Yoshiyama, Seemon Pines, Eleanor De Groot, Silvina Garcia Rubio, Peter Manini
  • Tetrahydrocarboline derivative
    Patent number: 9862721
    Abstract: An object of the present invention is to provide a drug having the inhibitory activity on ENPP2 which is a different target from that of the existing drug, as a medicament useful in a urinary excretion disorder patient for whom the existing drug has the insufficient effect. The present invention provides a compound represented by the general formula (I): (wherein definition of each group is as defined in the description) having the ENPP2 inhibitory activity, a salt thereof or a solvate thereof or a prodrug thereof, and an agent for preventing or treating urinary excretion disorder and/or improving symptoms thereof, containing them as an active ingredient.
    Type: Grant
    Filed: October 15, 2015
    Date of Patent: January 9, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Akira Ohata, Shingo Nakatani, Tetsuya Sugiyama, Takashi Morimoto
  • TRICYCLIC SPIRO COMPOUND
    Publication number: 20180002308
    Abstract: A medicinal agent for the prevention and/or treatment of diseases caused by EP4 receptor activation. A compound having antagonistic activity against the EP4 receptor is contained as an active ingredient in the medicinal agent. The compound represented by the following general formula (I) as defined in the specification, a salt, an N-oxide, or a solvate thereof, or a prodrug of these is useful as a medicinal component having antagonistic activity against the EP4 receptor for the prevention and/or treatment of diseases caused by EP4 receptor activation.
    Type: Application
    Filed: January 8, 2016
    Publication date: January 4, 2018
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masaki ASADA, Kousuke TANI, Masaya HIROBE, Satonori HIGUCHI, Kazuhiro FUCHIBE, Ryo OIKAWA, Tohru KOTANI, Hirotsugu TAKANO
  • Use of immunesuppressant receptor
    Patent number: 9856299
    Abstract: The present invention relates to use of an antagonist of BIR1 (B cell immunoglobulin receptor 1) related to the present invention, a method for screening the antagonist, in addition to subtype polypeptides of BIR1, the polynucleotide encoding them and antibodies for the polypeptides. BIR1 functions as an immunosuppressive receptor, and the antagonist of BIR1 has immunopotentive activity, which is able to use for preventing and/or treating a cancer, an immunodeficiency disease or an infectious disease.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: January 2, 2018
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tomoyuki Odani, Hideaki Tada, Kimiho Yamada
  • QUINOLINE DERIVATIVE
    Publication number: 20170349583
    Abstract: A compound represented by general formula (I) and having a quinoline skeleton has a strong Axl inhibitory activity, and therefore the compound can be an agent for treating Axl-related diseases, for example, cancer such as acute myeloid leukemia, chronic myeloid leukemia, melanoma, breast cancer, pancreatic cancer, and glioma, kidney diseases, immune system diseases, and circulatory system diseases.
    Type: Application
    Filed: December 24, 2015
    Publication date: December 7, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki INUKAI, Jun TAKEUCHI, Tomoko YASUHIRO
  • DIHYDROINDOLIZINONE DERIVATIVE
    Publication number: 20170349580
    Abstract: A compound represented by general formula (I) (wherein all symbols are as defined in the description) or a salt, solvate, N-oxide form or prodrug thereof is a potent FXIa inhibitor, has excellent oral absorption properties and kinetics in blood, can exert a potent anti-coagulation activity over a long period of time after being administered orally, and has a discrepancy between the anti-coagulation activity thereof and the CYP-inhibiting activity thereof. Therefore, the compound or the salt, solvate, N-oxide form or prodrug thereof can be used as an efficient prophylactic and/or therapeutic agent for vascular occlusive diseases.
    Type: Application
    Filed: December 9, 2015
    Publication date: December 7, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Motoyuki TANAKA, Takashi KONDO, Yasuo HIROOKA, Taihei NISHIYAMA, Atsushi HIRAMATSU, Tomoyuki KODA, Sho KOUYAMA
  • Trk-INHIBITING COMPOUND
    Publication number: 20170340634
    Abstract: The present invention provides a drug containing a compound having Trk-inhibiting activity as an active ingredient in prophylaxis and/or therapy for Trk-related diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease. A compound represented by the general formula (I), wherein all symbols represent the same meanings as described in the specification, a salt thereof, an N-oxide thereof, a solvate thereof or a prodrug thereof is useful as a drug component having Trk-inhibiting activity in prophylaxis and/or therapy of diseases such as pain, pruritus, lower urinary tract dysfunction, asthma, allergic rhinitis, inflammatory bowel disease or Chagas disease.
    Type: Application
    Filed: August 17, 2017
    Publication date: November 30, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Kazuya HASHIMURA, Masahiro IKURA, Masato HIGASHINO, Tetsuya YASUHIRO, Takeshi NAGAURA
  • KCNQ2-5 CHANNEL ACTIVATOR
    Publication number: 20170334855
    Abstract: The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.
    Type: Application
    Filed: August 8, 2017
    Publication date: November 23, 2017
    Applicant: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • Phenyl derivative
    Patent number: 9820980
    Abstract: The compound of the formula (I-1): wherein all the symbols have the same meanings as described in the specification, has two cyclic groups, particularly phenoxy groups at specific substitution positions and thus has high human S1P2 antagonistic activity. The compound may therefore be used as a therapeutic agent for S1P2-mediated diseases such as diseases resulting from vascular constriction, fibrosis, and respiratory diseases.
    Type: Grant
    Filed: April 4, 2016
    Date of Patent: November 21, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Atsushi Naganawa, Kensuke Kusumi, Kazuhiro Otsuki, Tetsuya Sekiguchi, Akito Kakuuchi, Koji Shinozaki, Hiroshi Yamamoto, Shigeyuki Nonaka
  • DIHYDRONAPHTHALENE DERIVATIVE
    Publication number: 20170327439
    Abstract: A compound represented by general formula (I) (wherein, all the symbols are as defined in the specification) has a selective S1P5 receptor agonist activity due to having a linker from a phenyl group to a cyclic substituent in a dihydronaphthalene skeleton; .i.e., due to having a short linker of one atom or less as L in general formula (I), and can therefore serve as an agent for treating S1P5-mediated disease, e.g., neurodegenerative disease such as schizophrenia.
    Type: Application
    Filed: December 3, 2014
    Publication date: November 16, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Kensuke KUSUMI, Haruto KURATA, Atsushi NAGANAWA, Yasuyo KODERA, Yuichi INAGAKI, Hiroya TAKIZAWA, Mark Allan WOLF, Joseph RAKER
  • THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES COMPRISING PD-1 AGONIST
    Publication number: 20170320949
    Abstract: Provided is a prophylactic, symptom progress-suppressive, and/or therapeutic agent for an autoimmune disease. The agent lowers the risk of infections and reduces the burden of administration to patients. The prophylactic, symptom progress-suppressive, and/or therapeutic agent includes a PD-1 agonist as an active ingredient and is administered (a) 1 to 10 times within one month from the first administration, (b) in a total PD-1 agonist dose of 20 to 1250 ?g/kg, and (c) without requiring administration for at least 3 months after the last administration.
    Type: Application
    Filed: June 9, 2017
    Publication date: November 9, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shiro SHIBAYAMA, Masamichi IMAI
  • KCNQ2-5 channel activator
    Patent number: 9809544
    Abstract: The present invention relates to a compound, 1-[(5-chloro-2-pyridinyl)methyl]-3-{2,6-dichloro-4-[(2S)-1,1,1-trifluoro-2-hydroxy-2-propanyl]phenyl}urea, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 23, 2015
    Date of Patent: November 7, 2017
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Kentaro Yashiro, Daisuke Wakamatsu, Tetsuji Saito
  • PURINONE DERIVATIVE HYDROCHLORIDE
    Publication number: 20170313706
    Abstract: The purinone derivative 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H-purin-8-one hydrochloride has Btk-selective inhibitory activity and, in addition to having excellent metabolic stability, it is a compound that exhibits a high level of solubility and absorption with respect to the free base and can be crystallized, hence it can serve as a therapeutic agent for diseases involving B cells and mast cells.
    Type: Application
    Filed: July 19, 2017
    Publication date: November 2, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • PURINONE DERIVATIVE
    Publication number: 20170313705
    Abstract: Compounds represented by general formula (I) (all of the symbols in the formula conform to the definitions in the Description) are compounds that, in addition to having a Btk-selective inhibitory activity, exhibit an excellent metabolic stability and can avoid hepatotoxicity or the like, and as a consequence can provide safe therapeutic agents for diseases in which B cells or mast cells participate.
    Type: Application
    Filed: July 13, 2017
    Publication date: November 2, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Shingo YAMAMOTO, Toshio YOSHIZAWA
  • COMPOUNDS
    Publication number: 20170305917
    Abstract: The present invention provides compounds of the general formula (I), their salts and N-oxides, and solvates and prodrugs thereof (wherein the characters are as defined in the description). The compounds of the general formula (I) are inhibitors of Factor XIa, so that they are useful in the prevention of and/or therapy for thromboembolic diseases.
    Type: Application
    Filed: July 7, 2017
    Publication date: October 26, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Steve COURTNEY, Chris YARNOLD, Stuart FLANAGAN, Gareth BRACE, John BARKER, Osamu ICHIHARA, Elise GADOULEAU, Anthony RICHARDSON, Takashi KONDO, Akira IMAGAWA, Shingo NAKATANI, Ryo SUZUKI, Sho KOUYAMA
  • Substance specific to human PD-1
    Patent number: 9783609
    Abstract: The present invention relates to a substance specific to human PD-1 comprising a part that recognizes human PD-1, a part that recognizes a membrane protein in cell membrane of human PD-1-expressing cells, and linkers. Since the substance specific to human PD-1 selectively can recognize human PD-1 and a membrane protein on cell membrane of human PD-1-expressing cells and can transmit inhibitory signal of human PD-1, it is useful for therapy and/or prevention of diseases caused by immunopathy.
    Type: Grant
    Filed: December 29, 2014
    Date of Patent: October 10, 2017
    Assignees: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Tasuku Honjo, Shiro Shibayama, Kazuhiko Takeda, Masayoshi Matsuo, Takao Yoshida, Masakazu Miyamoto
  • METHOD FOR ENHANCING IMMUNE CELL FUNCTION AND METHOD FOR ASSESSING IMMUNE CELL MULTIFUNCTIONALITY
    Publication number: 20170281569
    Abstract: The invention provides a method for enhancing immune cell function by activating various immune cells ex vivo and provides immune cells with enhanced function. The invention further provides an immune-related cell multifunctionality evaluation method. A biguanide antidiabetic drug selected from metformin, phenformin, and buformin is capable of enhancing immune cell multifunctionality by increasing CD8+T cells having a high ability to produce IL-2, INF?, and IFN?. The immune-related cell multifunctionality may be evaluated by comparing immune cells treated with a biguanide antidiabetic drug selected from metformin, phenformin, and buformin, with control immune cells untreated with the biguanide antidiabetic drug.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Applicants: NATIONAL UNIVERSITY CORPORATION OKAYAMA UNIVERSITY, Ono Pharmaceutical Co., Ltd.
    Inventors: Heiichiro UDONO, Shingo EIKAWA, Shin-ichi TOYOOKA
  • ALXR agonist compound
    Patent number: 9771357
    Abstract: The present invention provides a compound having ALXR agonist activity. Specifically, the invention provides a compound having ALXR agonist activity represented by general formula (I) wherein all the symbols are as defined in the specification, a salt thereof, a solvate thereof, or a prodrug thereof as well as an agent containing the same as an active ingredient for preventing and/or treating an ALXR-associated disease, such as an inflammatory bowel disease, an autoimmune disease, a chronic inflammatory disease, asthma, pulmonary fibrosis, atopic dermatitis, ischemia-reperfusion injury, myocardial infarction, or Alzheimer's disease.
    Type: Grant
    Filed: July 8, 2014
    Date of Patent: September 26, 2017
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Masahiko Terakado, Masaya Hirobe, Maki Iwahashi, Kousuke Tani, Tetsuya Sugiyama